genoSCORE™ combines Cytox’s proprietary technologies variaTECT™, a single nucleotide polymorphism (SNP) profiling array, with SNPfitR™analytical and interpretive software, to give a PRS that predicts any individual’s risk of developing Alzheimers disease.

Cytox is commercialising a hypothesis-free variant selection model that interrogates several hundred thousand [MM1] SNPs that are the most important for disease progression and development, identified through internal research combined with the latest public domain data.

Developers of new Alzheimer’s therapies, recruiting patients to clinical studies, can use genoSCORE™ to ensure selection of relevant patients – those most likely to experience near-term disease progression.

Home page of this offering   provided by Cytox